Imagene was founded with a clear mission to leverage technology in reaching the full potential of personalized medicine for cancer patients. Imagene deep learning technology profiles within minutes a broad range of cancer biomarkers from the digitized biopsy image alone, empowering physicians with immediate oncology intelligence to ensure optimal treatment for all cancer patients.
We are a diverse startup with a bright, passionate, and, most of all, fun team. Our success derives from our cutting-edge technology and a multidisciplinary team of data scientists, biologists, software engineers, and medical experts.
Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide. We were selected for The Marker ‘Most Promising Start-Ups for 2022’, and recognized by Frost & Sullivan for the 2023 Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis.
The fight against cancer is profound and the world needs talented and innovative people. If you are looking for a meaningful and challenging job – Join Us!